GliXogen Therapeutics
Ness Ziona, HaMerkaz, Israel
About GliXogen Therapeutics
GliXogen Therapeutics is a biopharmaceutical company developing a treatment to enhance remyelination in neurodegenerative disorders. All currently available approved medications for MS patients target the immune system and modulate it in a variety of ways, but they are unable to address the neurological damage that existed prior to the diagnosis. The progression of 75% of relapsing-remitting MS patients to the secondary progressive, more severe form of the disease is at least partially attributed to demyelination.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Funding stage: Seed
- Last round: Seed (Jan 2019)
- Website: glixogen.com
Industries & Categories
Biopharma, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/glixogen-therapeutics-2588874 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.